Monte Rosa Therapeutics Inc. (NASDAQ: GLUE)
$4.87
+0.6800 ( +16.23% ) 423.7K
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Market Data
Open
$4.87
Previous close
$4.19
Volume
423.7K
Market cap
$297.80M
Day range
$4.22 - $5.00
52 week range
$2.44 - $8.84
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
ars | Annual reports | 1 | Apr 26, 2024 |
def | Proxies and info statements | 5 | Apr 26, 2024 |
10-k | Annual reports | 148 | Mar 14, 2024 |
8-k | 8K-related | 77 | Mar 14, 2024 |
8-k | 8K-related | 66 | Jan 08, 2024 |
4 | Insider transactions | 1 | Jan 04, 2024 |
4 | Insider transactions | 1 | Jan 04, 2024 |
4 | Insider transactions | 1 | Jan 04, 2024 |
4 | Insider transactions | 1 | Jan 04, 2024 |
4 | Insider transactions | 1 | Jan 04, 2024 |